| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 68 | 92 | 77 | 95 | 75 | 89 | 99 | 84 | 191 | 146 | 128 | 135 | 132 | 205 | 126 | 145 | 145 | 142 | 121 | 159 | 97 | 171 | 146 | 199 | 110 | 178 | 189 | 202 | 141 | 195 | 183 | 264 |
| Expenses | 57 | 72 | 71 | 98 | 64 | 75 | 86 | 84 | 177 | 115 | 104 | 107 | 113 | 175 | 112 | 137 | 129 | 127 | 109 | 131 | 85 | 150 | 131 | 176 | 97 | 163 | 159 | 166 | 122 | 162 | 143 | 196 |
| EBITDA | 11 | 19 | 6 | -3 | 11 | 14 | 13 | 0 | 13 | 31 | 24 | 29 | 19 | 30 | 14 | 8 | 16 | 15 | 12 | 28 | 13 | 21 | 14 | 23 | 13 | 16 | 30 | 36 | 19 | 33 | 40 | 68 |
| Operating Profit % | 15 % | 18 % | 6 % | -8 % | 13 % | 14 % | 11 % | -2 % | 6 % | 8 % | 15 % | 4 % | 13 % | 13 % | 10 % | 4 % | 10 % | 9 % | 7 % | 16 % | 11 % | 11 % | 8 % | 10 % | 10 % | 4 % | 10 % | 15 % | 11 % | 16 % | 21 % | 24 % |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 7 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 7 | 8 | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 |
| Interest | 8 | 11 | 10 | 0 | 6 | 5 | 4 | -2 | 3 | 7 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -6 | -0 | -12 | -12 | -4 | 1 | 0 | -5 | 2 | 15 | 14 | 18 | 10 | 22 | 5 | 0 | 8 | 6 | 5 | 20 | 5 | 14 | 8 | 18 | 7 | 9 | 25 | 31 | 13 | 27 | 34 | 62 |
| Tax | 0 | -1 | -1 | -0 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | -17 | -2 | -2 | -1 | 0 | 1 | 0 | 1 | 9 | 4 | 4 | 1 | 7 | 6 | 6 | 5 | 10 | 3 | 6 | 8 | 14 |
| Net Profit | -6 | 0 | -12 | -12 | -4 | 0 | -1 | -5 | 2 | 13 | 12 | 35 | 12 | 23 | 6 | 0 | 7 | 5 | 3 | 11 | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 |
| EPS in ₹ | -4.70 | 0.34 | -9.50 | -9.29 | -3.30 | 0.34 | -0.78 | -4.38 | 1.60 | 10.55 | 9.44 | 28.45 | 8.86 | 17.32 | 4.22 | 0.17 | 5.16 | 3.99 | 2.46 | 8.27 | 0.88 | 7.44 | 5.13 | 7.86 | 0.92 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.53 |
Venus Remedies
Venus Remedies
1,344.10
+64.05
(5.00%)
Market Cap
1,796.66 Cr
PE Ratio
16.68
Volume
35,292.00
Day High - Low
1,344.10 - 1,344.10
52W High-Low
1,280.05 - 397.20
Key Fundamentals
Market Cap
1,796.66 Cr
EPS
76.89
PE Ratio
16.68
PB Ratio
2.58
Book Value
496.56
EBITDA
147.28
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
8.08
Debt to Equity
0.04
Actual
Company News
View All News
Venus Remedies reported a consolidated net profit of ₹102.78 crore for FY26, up from ₹45.31 crore in the previous year. The board recommended a final dividend of ₹10 per share and scheduled the AGM for August 20, 2026.
Venus Remedies Gets Saudi FDA Nod for Plerixafor10 days ago
Venus Remedies secures Saudi FDA approval for Plerixafor, marking its first global marketing authorization for this specialty cancer treatment.
Venus Remedies urges KYC update
May 21, 2026
May 21, 2026Venus Remedies Limited shared social media links to raise awareness among shareholders about updating KYC details. The communication was made pursuant to Regulation 30 of SEBI regulations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,796.50 | #1 4,31,040.53 | 37.54 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 45.78 | |
6,553.50 | 1,73,974.83 | 68.85 | 10,560.00 | 8.73 | 2,520 | 13.44 | 45.06 | |
4,350.40 | 1,47,237.30 | 69.56 | 13,753.00 | 19.18 | 2,028 | -26.91 | 48.80 | |
1,390.30 | 1,12,305.75 | 29.25 | 27,711.70 | -2.46 | 3,783 | -55.32 | 56.75 | |
1,091.20 | 1,09,800.25 | 21.16 | 26,719.70 | 13.65 | 5,242 | 7.82 | 74.27 | |
1,290.40 | 1,07,702.34 | 26.16 | 33,593.30 | -0.44 | 3,998 | -86.05 | 47.28 | |
2,262.90 | 1,03,424.31 | #1 19.40 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 44.88 | |
2,320.20 | 95,779.03 | 50.66 | 14,277.60 | 12.03 | 1,750 | 31.75 | 44.68 | |
1,433.70 | 83,269.53 | 23.73 | 33,384.70 | 3.21 | 3,376 | 1.99 | 47.10 | |
1,388.40 | 74,953.69 | 82.57 | 6,812.90 | #1 21.03 | 884 | 21.18 | 76.63 |
Growth Rate
Revenue Growth
15.07 %
Net Income Growth
123.55 %
Cash Flow Change
131.80 %
ROE
38.36 %
ROCE
51.90 %
EBITDA Margin (Avg.)
49.09 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Fixed Assets | 444 | 453 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 283 |
| Current Assets | 233 | 277 | 259 | 260 | 265 | 294 | 234 | 278 | 323 | 360 | 452 | 395 |
| Capital Work in Progress | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 129 |
| Other Assets | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 0 |
| Total Equity & Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 |
| Current Liabilities | 163 | 193 | 197 | 230 | 264 | 225 | 97 | 93 | 83 | 79 | 136 | 162 |
| Non Current Liabilities | 222 | 212 | 180 | 159 | 137 | 96 | 58 | 47 | 58 | 60 | 19 | 28 |
| Total Equity | 457 | 438 | 389 | 362 | 333 | 323 | 400 | 440 | 460 | 488 | 561 | 664 |
| Reserve & Surplus | 445 | 426 | 376 | 350 | 320 | 311 | 374 | 427 | 447 | 474 | 548 | 650 |
| Share Capital | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 4 | -4 | 0 | -1 | -0 | 27 | 14 | -22 | 28 | 9 |
| Investing Activities | -67 | 3 | -18 | 9 | -11 | -5 | 57 | -17 | -58 | -9 | -77 |
| Operating Activities | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 |
| Financing Activities | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -10 | -1 | -1 | -1 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 35.89 % | 40.81 % | 40.81 % | 40.81 % | 40.81 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % | 41.76 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.03 % | 1.59 % | 1.48 % | 1.06 % | 1.18 % | 1.11 % | 1.34 % | 2.24 % | 1.86 % | 2.26 % | 2.80 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.15 % | 0.00 % | 0.00 % | 0.11 % | 0.75 % | 1.03 % | 1.20 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 54.71 % | 51.21 % | 51.95 % | 52.18 % | 51.72 % | 49.97 % | 50.18 % | 50.04 % | 49.24 % | 48.66 % | 48.20 % | 47.25 % | 46.89 % | 46.25 % | 45.31 % | 45.42 % | 46.81 % | 47.70 % | 45.30 % | 45.16 % | 44.39 % |
| Others | 9.39 % | 7.98 % | 7.24 % | 7.01 % | 7.48 % | 8.27 % | 7.91 % | 8.05 % | 8.85 % | 9.43 % | 8.86 % | 9.24 % | 9.73 % | 10.78 % | 11.61 % | 11.71 % | 10.09 % | 8.19 % | 10.33 % | 9.80 % | 9.85 % |
| No of Share Holders | 13,829 | 13,846 | 16,617 | 18,231 | 19,952 | 21,189 | 22,015 | 22,243 | 21,719 | 20,498 | 19,267 | 19,560 | 19,913 | 19,614 | 19,557 | 19,771 | 19,982 | 19,307 | 17,725 | 18,606 | 18,403 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Sept 2024 |  Annual General Meeting | NA | 23 Sept 2024 | 339.15 | 342.30 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 345.90 | 343.60 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 294.10 | 288.35 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 344.05 | 355.60 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 540.15 | 524.40 |
| 22 Aug 2025 | Annual General Meeting | NA | 22 Aug 2025 | 431.95 | 494.60 |
| 10 Nov 2025 | Quarterly Result Announcement | NA | 10 Nov 2025 | 441.00 | 448.85 |
| 29 Jan 2026 | Quarterly Result Announcement | NA | 29 Jan 2026 | 784.80 | 745.45 |
| 26 May 2026 | Quarterly Result Announcement | NA | 26 May 2026 | 939.70 | 1,136.15 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoCorporate Action-Board to consider Dividend6 days ago
6 days agoAdoption Of MOA & AOA As Per The Companies Act 20136 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Change in Management6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Dividend Updates6 days ago
6 days agoFinancial Results For The Financial Year 2025-26.6 days ago
6 days agoBoard Meeting Outcome for Outcome Of Board Meeting Dated 26.05.20266 days ago
6 days agoVenus Remedies Receives Saudi FDA Approval For Plerixafor - Its First Maketing Authorization For The Specialty Oncology Therapy Globally10 days ago
10 days agoSocial Media Post On KYC UpdationMay 21, 2026
May 21, 2026Corporate Action-Board to consider DividendMay 15, 2026
May 15, 2026Board Meeting Intimation for Board Meeting Scheduled For 26Th May 2026.May 15, 2026
May 15, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2026
May 06, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 05, 2026
May 05, 2026Disclosure Of Social Media Post On Transfer Of Physical Shares.May 04, 2026
May 04, 2026Social Media PostApr 08, 2026
Apr 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2026
Apr 08, 2026Disclosures Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011Apr 04, 2026
Apr 04, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Social Media Post Pertaining To Transfer Of Physical Shares.Mar 10, 2026
Mar 10, 2026Disclosure Of Information Received From Promoter Group Companies Regarding Merger.Mar 02, 2026
Mar 02, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2026
Jan 31, 2026Unaudited Standalone And Consolidated Financial Results As On 31St December 2025Jan 29, 2026
Jan 29, 2026Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January 2026Jan 29, 2026
Jan 29, 2026Venus Remedies Awarded With Rs. 117750000 Incentive Under The PLI Scheme.Jan 22, 2026
Jan 22, 2026Board Meeting Intimation for The Meeting Of Board Of Directors Is Scheduled To Be Held On 29Th January 2026.Jan 19, 2026
Jan 19, 2026Updation On UIDN For Financial Results As On 30Th September 2025Jan 13, 2026
Jan 13, 2026Grant Of Marketing Authorisation In IndonesiaJan 08, 2026
Jan 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2026
Jan 06, 2026Copy Of Newspaper Notice Pertaining To Physical Transfer Of Shares.Dec 26, 2025
Dec 26, 2025Closure of Trading WindowDec 23, 2025
Dec 23, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited.Dec 13, 2025
Dec 13, 2025Shares Re-Lodged For Transfer Cum Demat Pursuant To SEBI Circular No. SEBI/HO/MIRSD/MIRSD-Pod/P/CIR/2025/97 Dated July 2 2025 For The Period July 7 2025 To November 30 2025Dec 12, 2025
Dec 12, 2025Venus Remedies Marks Completion Of AMR Licensing Milestones With Final ?11 Crore PaymentDec 08, 2025
Dec 08, 2025Update On Resolution Of Income Tax Matters And Elimination Of Contingent Liability.Dec 01, 2025
Dec 01, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies LimitedNov 28, 2025
Nov 28, 2025Clarification On Movement In VolumeNov 20, 2025
Nov 20, 2025Clarification sought from Venus Remedies LtdNov 20, 2025
Nov 20, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies LimitedNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Nov 12, 2025Unaudited Financial Results As On 30Th September 2025Nov 10, 2025
Nov 10, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 10Th November 2025Nov 10, 2025
Nov 10, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares.Oct 28, 2025
Oct 28, 2025Board Meeting Intimation for Board Meeting Scheduled To Be Held On 10Th November 2025.Oct 27, 2025
Oct 27, 2025SEBI Circular - Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares - Monthly Report.Oct 18, 2025
Oct 18, 2025Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares.Oct 10, 2025
Oct 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 07, 2025
Oct 07, 2025Closure of Trading WindowSep 22, 2025
Sep 22, 2025Social Media CommunicationSep 20, 2025
Sep 20, 2025Social Media Post On Saksham Niveshak Campaign By IEPF.Sep 11, 2025
Sep 11, 2025Technical Indicators
RSI(14)
Neutral 77.12
ATR(14)
Less Volatile 55.88
STOCH(9,6)
Overbought 95.97
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 29.91
ADX(14)
Weak Trend 21.92
UO(9)
Bearish 76.68
ROC(12)
Uptrend And Accelerating 37.39
WillR(14)
Overbought 0.00
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
